Bright Light Therapy: A Novel Non-Pharmacological Approach to Parkinson’s Disease
Objective: To assess the effectiveness of Bright Light Therapy (BLT) in ameliorating symptoms and neuropathology in an α-synuclein preformed fibril (α-syn PFF) induced Parkinson’s disease…LRRK2 G2019S mutant damages mitochondrial transfer by a Drp1-STX17 depend pathway in Parkinson’s disease
Objective: We focus on the novel endogenous neural repair function that comes from the mitochondrial transfer, and we aim to elucidate the molecular mechanism by…Insulin-like growth factor 2 and inflammatory response in Parkinson Disease: Potential predictor marker
Objective: Clinical diagnosis Parkinson's disease (PD), is often difficult, with the appearance of motor symptoms hence the importance of identify non-invasive early markers is a…Development of an AAV-mediated artificial miRNA targeting human alpha-synuclein (α-syn) as a potential gene therapy for Synucleinopathies
Objective: To develop an adeno-associated virus (AAV)-based artificial miRNA (miRNA) system targeting human α-syn. Background: Synucleinopathies such as Parkinson’s disease (PD) and Multiple System Atrophy…Pure Autonomic Failure As a Severe “Body-First Subtype” of Lewy Body Disease: A Multimodal Imaging Study of the Autonomic Nervous System
Objective: Using multi-modal imaging this study aimed to characterize the deterioration of the parasympathetic and sympathetic nervous system in pure autonomic failure (PAF) in comparison…Hippocampal volume in Parkinson’s Disease in south India
Objective: To analyse hippocampal volume differences among the patients with Parkinson’s disease and healthy individuals. Background: In humans, hippocampus is involved in regulation of emotions,…Quantification of Neuroinflammation and White Matter Injury in Parkinson Disease Using Diffusion Basis Spectrum Imaging
Objective: To investigate differences in white matter (WM) using Diffusion Basis Spectrum Imaging (DBSI) between participants with Parkinson’s disease (PD) and controls and to examine…Comparing 18F-AV133 VMAT2 PET and DATscan as Markers of Parkinson’s Disease Severity and Progression
Objective: Compare VMAT2 PET signal with DATscan at baseline and over time, and evaluate their correlations with MDS-UPDRS III. Background: DATscan is a Parkinson’s disease…The Contribution of APOE4 Genotype on Structural MRI in Parkinson’s Disease: A Study from the PPMI Cohort
Objective: To assess the contribution of Apolipoprotein E4 (APOE4) in Parkinson’s Disease (PD)-related cognitive impairment by analyzing its impact on Gray Matter Volume (GMV). Background:…Effects of striatal dopamine depletion and altered brain metabolism on Parkinson’s disease
Objective: To investigate the relationship between striatal dopamine depletion, altered brain metabolism, motor deficits, and cognitive dysfunction in Parkinson’s disease (PD) Background: PD shows degeneration…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.